Regarding BET inhibitors, birabresib monotherapy was evaluated in 22 DLBCL patients, which showed an ORR of 10% and a high incidence of AEs, including thrombocytopenia and anemia affecting more than 90% (NCT01713582) [143]. Here, DNER is linked to diffuse large B-cell lymphoma.